接受卡度尼利单抗治疗的胃腺癌并发肺肿瘤血栓性微血管病1例并文献复习
Cadonilimab for Gastric Adenocarcinoma Complicated by Pulmonary Tumor Thrombotic Microangiopathy: A Case Report and Literature Review
DOI: 10.12677/ACM.2024.143779, PDF,   
作者: 成锐琪, 陈 剑*：青岛大学附属烟台毓璜顶医院肿瘤内科，山东 烟台；陈雅琪：山东第二医科大学临床医学院，山东 潍坊
关键词: 胃癌；肺肿瘤血栓性微血管病；血栓性微血管病；卡度尼利单抗；免疫检查点抑制剂；Gastric Cancer； Pulmonary Tumor Thrombotic Microangiopathy； Thrombotic Microangiopathy； Ca-donilimab； Immune Checkpoint Inhibitors
摘要: 肺肿瘤血栓性微血管病(PTTM)是一种罕见的、快速进展且致命的肿瘤相关并发症，患者通常在发病后短期内进展至死亡。目前，国内报道的病例多因呼吸系统症状首诊，发病前无明确的肿瘤病史，临床早期诊断困难，接受系统性抗肿瘤治疗后肿瘤控制稳定却仍出现PTTM的病例更鲜有报道。因此我们报道了1例在接受免疫治疗后出现肺肿瘤血栓性微血管病的胃腺癌患者，并结合相关文献对病例进行总结，为临床中对肺肿瘤血栓性微血管病的早期鉴别及诊治提供经验。
Abstract: Pulmonary Tumor Thrombotic Microangiopathy (PTTM) is a rare, rapidly progressive and fatal tu-mor-related complication, and patients usually progress to death within a short period of time after onset. Currently, most of the cases reported in China were first diagnosed with respiratory symp-toms without a clear history of tumor prior to the onset of the disease, which made early clinical di-agnosis difficult, and fewer cases were reported in which PTTM occurred despite stable tumor con-trol after receiving systemic antitumor therapy. Therefore, we report a case of gastric adenocarci-noma patient who developed PTTM after receiving immunotherapy, and summarize the case with relevant literature to provide experience in early identification and diagnosis of PTTM in clinical practice.
文章引用：成锐琪, 陈雅琪, 陈剑. 接受卡度尼利单抗治疗的胃腺癌并发肺肿瘤血栓性微血管病1例并文献复习[J]. 临床医学进展, 2024, 14(3): 840-845. https://doi.org/10.12677/ACM.2024.143779

参考文献

[1] Von Herbay, A., Illes, A., Waldherr, R. and Otto, H.F. (1990) Pulmonary Tumor Thrombotic Microangiopathy with Pulmonary Hypertension. Cancer, 66, 587-592. [Google Scholar] [CrossRef] 
[2] Godbole, R.H., Saggar, R. and Kamangar, N. (2019) Pulmonary Tumor Thrombotic Microangiopathy: A Systematic Review. Pulmonary Circulation, 9, 1-13. [Google Scholar] [CrossRef] [PubMed]
[3] Uruga, H., Fujii, T., Kurosaki, A., Hanada, S., Takaya, H., Miyamoto, A., et al. (2013) Pulmonary Tumor Thrombotic Microangiopathy: A Clinical Analysis of 30 Autopsy Cases. Internal Medicine, 52, 1317-1323. [Google Scholar] [CrossRef] [PubMed]
[4] 占丰富, 张孝斌, 黄茂宏, 等. 肺肿瘤血栓性微血管病2例报道并文献复习[J]. 疑难病杂志, 2022, 21(7): 736-741.
[5] Sato, N., Tasaki, T., Noguchi, H., Irie, K. and Naka-yama, T. (2019) The Pathological Challenge of Establishing a Precise Diagnosis for Pulmonary Tumour Thrombotic Mi-croangiopathy: Identification of New Diagnostic Criteria. Histopathology, 74, 892-901. [Google Scholar] [CrossRef] [PubMed]
[6] Kamada, H., Ota, H., Terui, Y., Sugimura, K., Fukui, S., Shimokawa, H., et al. (2020) Three Cases of Pulmonary Tumor Thrombotic Microangiopathy (PTTM): Challenge in Antemortem Diagnosis Using Lung Perfusion Blood Volume Images by Dual-Energy Computed Tomography. European Journal of Radiology Open, 7, 100212. [Google Scholar] [CrossRef] [PubMed]
[7] Kumar, N., Price, L.C., Montero, M.A., Dimopoulos, K., Wells, A.U. and Wort, S.J. (2015) Pulmonary Tumour Thrombotic Microangiopathy: Unclassifiable Pulmonary Hypertension. European Respiratory Journal, 46, 1214-1217. [Google Scholar] [CrossRef] [PubMed]
[8] Aklilu, A.M.M. and Shirali, A.C.C. (2023) Chemothera-py-Associated Thrombotic Microangiopathy. Kidney360, 4, 409-422. [Google Scholar] [CrossRef] 
[9] Font, C., De Herreros, M.G., Tsoukalas, N., Brito-Dellan, N., Esposito, F., Escalante, C., et al. (2022) Thrombotic Microangiopathy (TMA) in Adult Patients with Solid Tumors: A Challenging Complication in the Era of Emerging Anticancer Therapies. Supportive Care in Cancer, 30, 8599-8609. [Google Scholar] [CrossRef] [PubMed]
[10] Pang, X., Huang, Z., Zhong, T., Zhang, P., Wang, Z.M., et al. (2023) Cadonilimab, a Tetravalent PD-1/CTLA-4 Bispecific Antibody with Trans-Binding and Enhanced Target Binding Avidity. mABs, 15, Article 2180794. [Google Scholar] [CrossRef] [PubMed]
[11] Horino, T., Eguchi, T., Inotani, S., Hirose, A., Ishihara, M., Yagyu, K., et al. (2023) Overlap of Thrombotic Microangiopathy and Mesangial Proliferative Glomerulonephritis Caused by Combination Therapy with Atezolizumab and Bevacizumab. Internal Medicine, 62, 91-94. [Google Scholar] [CrossRef] [PubMed]
[12] Lancelot, M., Miller, M.J., Roback, J. and Stowell, S.R. (2021) Refractory Thrombotic Thrombocytopenic Purpura Related to Checkpoint Inhibitor Immunotherapy. Transfusion, 61, 322-328. [Google Scholar] [CrossRef] [PubMed]
[13] Muniz, T.P., Patriquin, C.J. and Saibil, S.D. (2021) Presumed Complement-Mediated, Checkpoint Inhibitor-Induced, Thrombotic Microangiopathy in a Patient with Metastatic Mela-noma. BMJ Case Reports, 14, e242075. [Google Scholar] [CrossRef] [PubMed]
[14] Utsu, Y., Kawakami, M., Arai, H., Hisamatsu, H., Yano, Y. and Terada, J. (2023) Pulmonary Tumor Thrombotic Microangiopathy during Good Response to Immuno-Chemotherapy for Advanced Non-Small Cell Lung Cancer: A Case Report. BMC Pulmonary Medicine, 23, Article No. 124. [Google Scholar] [CrossRef] [PubMed]
[15] Toyonaga, H., Tsuchiya, M., Sakaguchi, C., Ajimizu, H., Nakanishi, Y., Nishiyama, S., et al. (2017) Pulmonary Tumor Thrombotic Microangiopathy Caused by a Parotid Tumor: Early Antemortem Diagnosis and Long-Term Survival. Internal Medicine, 56, 67-71. [Google Scholar] [CrossRef] [PubMed]
[16] 郑天萍, 昝瑜珉, 许伟, 等. 宫颈鳞癌并发肺肿瘤血栓性微血管病1例并文献复习[J]. 南京医科大学学报(自然科学版), 2023, 43(10): 1470-1474.
[17] 杜竺蔓, 刘春涛. 肺肿瘤血栓性微血管病研究进展[J]. 临床肺科杂志, 2021, 26(5): 780-783.

为你推荐